Michael T. Lotze, MD, FACS is Professor of Surgery, Immunology, and Bioengineering; Director of the DAMP Laboratories at the UPMC Hillman Cancer Center within the University of Pittsburgh Medical Center Hillman Cancer Center. He is a long-time SITC enthusiast, attending his first meeting in Williamsburg in 1989, presiding over the Society in 1998, and launching both the Primer on Tumor Immunology as well as the SITC Clinical Immuno-Oncology Network (SCION) to advance the most rigorous and robust clinical protocols in immunotherapy of cancer. Dr. Lotze is the co-inventor of 10 patents in dendritic cell vaccines and antigen discovery, 13 patents in tumor infiltrating lymphocyte (TIL) therapy (while at Lion/Iovance Biotherapeutics 2016-2018), and additional patents at Nurix Therapeutics (2020-2023), where he served as Chief Cell Therapy Officer 2020-2023. He is an award-winning NCI-trained scientist (1978-1990), the inaugural Director of Surgical Oncology at Pitt (1990-2000), former Vice President of Research at GlaxoSmithKline (1999-2001), founding director of the UPCI Academy, and innovative educator as a prolific clinician-scientist/tumor immunologist with over 500 publications and several books. He is currently Editor in Chief of the Journal for Immunotherapy of Cancer (2024).
Michael T. Lotze, MD, FACS
